ImpriMed, Inc.
Veterinary Medicine · Artificial Intelligence
Sponsors visas
Lately:5 news stories in 90 daysFollow changes →
Facts
as of Nov 17, 2026ImpriMed uses live-cell testing and AI to predict drug response for veterinary oncology, human blood cancers, and pharma drug development. Based in Palo Alto & Seoul.
- Headquarters
- Palo Alto, United States
- Founded
- 2017
- Employees
- 51-200estimated range
- Website
- imprimedicine.com
These are the key facts about ImpriMed, Inc. on Alion as of Nov 17, 2026. ImpriMed, Inc. is headquartered in Palo Alto, United States. It was founded in 2017. The latest round is Series A of $23M, announced in 2023.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Visa
Full chapter →Named in the work visa registers of United States.
United StatesUS 1
#5,755 of 8,997 sponsors
1H-1B filings in 12 months
$113kMedian offered salary
0Open roles in United States
Who they sponsor
The salary offered for each occupationVisa pass · 90 credits In the register as ImpriMed, Inc., Palo Alto, CA (+1 more)
Other sponsors in the same field
Alert me
US Department of Labor · latest filing Apr 29, 2026
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Palo Alto United States | Headquarters | 0 |
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$23MTotal raised
Series ALatest round
1Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
2023
$23M
Sources: funding announcements, grant and company registers
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 292026
News · Pharmacy Times
AI-powered drug response prediction technology is revolutionizing veterinary and human oncology by enabling personalized treatment plans through live cell testing, machine learni…
Sep 292026
News · Pharmacy Times
Dogs share a number of cancers with humans, including melanoma, non-Hodgkin lymphoma, leukemia, and osteosarcoma.
Sep 292026
News · dvm360
ImpriMed has announced the launch of the Drug Response Predictions service used to forecast how each dog will respond to certain oncology treatments.
Sep 292026
News · dvm360
A new study showed that this cell-sizing method is useful for characterizing feline lymphoma and predicting patient survival time
Sep 172026
News · tmcnet.com
Jul 12026
Press release · businesswire
ImpriMed CEO Dr. Sungwon Lim to speak at the NCI's functional precision medicine workshop, underscoring the company's leadership in the growing field.
Sources: the outlets named on each headline, each story once
